4D Molecular Therapeutics Inc (FDMT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2017 | 12-2006 | 12-2005 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -56,693 | -49,306 | N/A | N/A | N/A |
| Depreciation Amortization | 1,443 | 1,004 | N/A | N/A | N/A |
| Accounts receivable | -508 | 146 | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | 43 | 533 | N/A | N/A | N/A |
| Other Working Capital | -712 | 259 | N/A | N/A | N/A |
| Other Operating Activity | 5,518 | 10,653 | 0 | 0 | 0 |
| Operating Cash Flow | $-50,909 | $-36,711 | $N/A | $N/A | $N/A |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -1,000 | -3,203 | N/A | N/A | N/A |
| Investing Cash Flow | $-1,000 | $-3,203 | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 206,515 | -2,185 | N/A | N/A | N/A |
| Other Financing Activity | 72,468 | -10 | 0 | 0 | 0 |
| Financing Cash Flow | $278,983 | $-2,195 | $N/A | $N/A | $N/A |
| Beginning Cash Position | 49,652 | 91,761 | N/A | N/A | N/A |
| End Cash Position | 276,726 | 49,652 | N/A | N/A | N/A |
| Net Cash Flow | $227,074 | $-42,109 | $N/A | $N/A | $N/A |
| Free Cash Flow | |||||
| Operating Cash Flow | -50,909 | -36,711 | N/A | N/A | N/A |
| Capital Expenditure | -1,000 | -3,203 | N/A | N/A | N/A |
| Free Cash Flow | -51,909 | -39,914 | 0 | 0 | 0 |